Stratos Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stratos Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$949K	Sell	16,585 -4,211	-20%	-$231K	0.05%	284
2026 Q1	$1.17M	Hold	20,796	–	–	0.07%	250
2025 Q4	$1.24M	Sell	20,796 -6,074	-23%	-$331K	0.06%	283
2025 Q3	$1.46M	Sell	26,870 -8,398	-24%	-$480K	0.07%	268
2025 Q2	$1.94M	Sell	35,268 -400	-1%	-$23.6K	0.1%	208
2025 Q1	$2.52M	Sell	35,668 -7,774	-18%	-$523K	0.14%	143
2024 Q4	$2.86M	Sell	43,442 -400	-0.9%	-$26.8K	0.14%	154
2024 Q3	$3.08M	Sell	43,842 -2,022	-4%	-$169K	0.14%	157
2024 Q2	$3.78M	Hold	45,864	–	–	0.19%	122
2024 Q1	$4.01M	Hold	45,864	–	–	0.24%	102
2023 Q4	$4.42M	Hold	45,864	–	–	0.25%	113
2023 Q3	$4.06M	Sell	45,864 -2,550	-5%	-$227K	0.27%	105
2023 Q2	$4.2M	Buy	48,414 +1,600	+3%	+$151K	0.3%	92
2023 Q1	$4.55M	Buy	46,814 +9,755	+26%	+$1.01M	0.35%	79
2022 Q4	$3.84M	Buy	+37,059	New	+$3.48M	0.32%	92

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Stratos Wealth Advisors's BMRN Position: Q2 2026 in Review

Stratos Wealth Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q2 2026, selling an estimated $231K and leaving 16,585 shares worth $949K. The position accounts for 0.05% of the portfolio, ranked #284.

Stratos Wealth Advisors first reported a position in BMRN in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.55M in Q1 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Stratos Wealth Advisors held 16,585 shares of BioMarin Pharmaceuticals worth $949K as of Q2 2026.
Stratos Wealth Advisors sold 4,211 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $231K.
BioMarin Pharmaceuticals made up 0.05% of Stratos Wealth Advisors's portfolio in Q2 2026, its #284 holding.
Stratos Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Stratos Wealth Advisors's BioMarin Pharmaceuticals position peaked at $4.55M in Q1 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.